Rachel Thorn represents companies in commercial arbitrations, both US domestic and international, and in investment-treaty disputes (ICSID, UNCITRAL). She has extensive expertise in the Federal Arbitration Act, the US leading domestic arbitration rules (AAA, JAMS, CPR) and is advising on issues involving mass arbitrations. Rachel also represents clients around the world in arbitrations under the rules of the major arbitral institutions (ICC, ICDR, LCIA, SCIA, HKIAC). Her practice includes arbitration-related litigation in the United States Courts, including actions to compel or stay arbitration proceedings, and actions to vacate, confirm or enforce arbitration awards under the FAA and New York Conventions. In addition, she regularly counsels clients in transactional matters. Her experience spans many industries, including life science, technology, post M&A disputes, and dispute involving joint ventures and long-term cooperation agreements, energy and infrastructure.

Download full bio 


  • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 

  • X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics 

  • Forty Seven in its Exclusive License Agreement with Ono Pharmaceutical 

  • GENFIT SA in its Licensing and Collaboration Agreement with Terns Pharmaceuticals 

  • I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment 

  • View all


  • University of Chicago Law School
    JD, 1996

  • University of Wisconsin, Madison
    BA, 1992

Admissions & Credentials

New York

England & Wales

Rankings & Accolades

    Chambers: International Arbitration: Counsel

    Legal 500 US: International Arbitration

    Benchmark Litigation: Future Star (2014)

    Global Arbitration Review: Top 45 Under 45 (2011)